NYSE:BXCapital Markets
Blackstone Extends Reach Into Life Sciences And AI Data Infrastructure
Blackstone (NYSE:BX) committed up to US$400 million to Teva's autoimmune drug program in a recent life sciences deal.
The firm also arranged a US$2 billion, utility backed power financing package for QTS data centers to support AI focused capacity.
These transactions sit alongside Blackstone's traditional alternatives platform and indicate additional sector exposure in health and digital infrastructure.
For investors, these moves illustrate how NYSE:BX is putting capital to work in areas...